Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 Jan;340(1):11–18. doi: 10.1124/jpet.111.186858

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics

PMC Copyright notice

Fig. 6. — Effects of WIN55,212-2 on pERK1/2 in the presence or absence of AM251, wortmannin, or PD98059 in rat NTS and RVLM. Changes in pERK1/2 in rat NTS (A-D) and RVLM (E-H) elicited by intracisternal WIN55,212-2 in animals pretreated with vehicle (control) (A and E), the CB₁R antagonist AM251(30 μg/rat; B and F), the PI3K inhibitor wortmannin (Wort; 0.4 μg/rat; C and G), or the MEK/ERK1/2 inhibitor PD98059 (PD98; 5 μg/rat; D and H) are shown. Data are presented as the integrated density ratio of phosphorylated ERK1 (pERK1/2) to total ERK1/2 (tERK1/2) and expressed as percentage of vehicle (control) value. Values are mean ± S.E.M. of four to five observations. Symbols denote statistical significance (P < 0.05) based on comparing the responses elicited by WIN55,212-2 alone or in the presence of the pharmacological intervention versus vehicle as well as treatment control, AM251, wortmannin, or PD98059 values.